Item 1.01 Entry into a Material Definitive Agreement

On October 13, 2020, MacroGenics, Inc. (the "Company") entered into a Commercial Supply Agreement (the "Commercial Supply Agreement") with Incyte Corporation ("Incyte"). The Company and Incyte are parties to that certain Global Collaboration and License Agreement, dated October 24, 2017, in which the Company granted to Incyte an exclusive license to develop, manufacture and commercialize retifanlimab (the "Collaboration and License Agreement"). The Commercial Supply Agreement was entered into as contemplated by the Collaboration and License Agreement, pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (formerly designated as MGA012 by the Company). The Company plans to manufacture commercial retifanlimab at its 5 x 2,000L scale GMP facility in Rockville, MD.

Unless terminated earlier, the term of the Commercial Supply Agreement will expire upon the expiration of Incyte's obligation to pay royalties under the Collaboration and License Agreement. The Commercial Supply Agreement also includes customary provisions relating to, among others, production forecasting, delivery, inspection procedures, warranties, confidentiality and indemnification. The foregoing description of the Commercial Supply Agreement does not purport to be complete and is qualified in its entirety by reference to the complete Commercial Supply Agreement, which will be filed in redacted form as an exhibit to the Company's Annual Report on Form 10-K for the year ending December 31, 2020.

© Edgar Online, source Glimpses